Federal Register / Vol. 82, No. 213 / Monday, November 6, 2017 / Notices 51439 

Registrant, both with respect to the 

volume of drugs being diverted and by 

denying that he was engaged in 

diverting and abusing the controlled 

substances. As explained above, 

Registrant’s and Chapman’s misconduct 

in diverting drugs, which the latter 

personally abused, was actionable 

misconduct under both Factor Four 

(compliance with applicable laws 

related to controlled substances) and 

Factor Five (other conduct which may 

threaten public health and safety). As 

the DI explained, had Chapman been 

candid during the June 30, 2016 

interview, he and his colleagues ‘‘would 

have pursued immediate criminal action 

against Chapman’’ as well as 

administrative action against Registrant. 

Indeed, Chapman’s subsequent 

admissions during the July 22, 2016 

interview supported both criminal 

charges against Chapman and the 

Immediate Suspension Order. 

Accordingly, I conclude that the 

evidence with respect to Factor Five 

establishes that Registrant’s principal 

was abusing controlled substances and 

that he made several materially false 

statements to DEA investigators. I also 

conclude that these acts constitute 

actionable misconduct which may 

threaten public health and safety. 

Summary of Factors Four and Five and 

Imminent Danger 

As found above, the Government’s 

evidence establishes that Registrant 

unlawfully distributed controlled 

substances to Chapman and failed to 

maintain required records. The evidence 

also establishes that Registrant’s 

principal and pharmacist in charge 

unlawfully possessed controlled 

substances, destroyed records that 

Registrant was required to maintain, 

abused controlled substances and made 

materially false statements to DEA 

Investigators. I therefore find that 

Registrant has committed such acts as to 

render its registration inconsistent with 

the public interest. 21 U.S.C. 824(a)(4). 

For purposes of the imminent danger 

inquiry, these findings also support the 

conclusion that Registrant has ‘‘fail[ed] 

. . . to maintain effective controls 

against diversion or otherwise comply 

with the obligations of a registrant 

under’’ the CSA. 21 U.S.C. 824(d)(2). 

Also, the evidence that Chapman was 

diverting 200 to 300 milligrams of 

narcotics per day, which he then abused 

(along with the evidence showing that 

he was hospitalized for an overdose on 

multiple occasions), establishes that 

there was ‘‘a substantial likelihood of an 

immediate threat that death, serious 

bodily harm, or abuse of a controlled 

substance [would] occur in the absence 

of the immediate suspension of 

[Registrant’] registration.’’ Id. I therefor 

affirm the issuance of the Immediate 

Suspension Order. 

Pursuant to 21 U.S.C. 824(f), ‘‘[u]pon 

a revocation order becoming final, all 

. . . controlled substances’’ seized 

pursuant to a suspension order ‘‘shall be 

forfeited to the United States’’ and ‘‘[a]ll 

right, title, and interest in such 

controlled substances shall vest in the 

United States upon a revocation order 

becoming final.’’ As the Agency has 

previously held, a registrant cannot 

defeat the effect of this provision by 

allowing its registration to expire.’’ 

S & S Pharmacy, Inc., d/b/a Platinum 

Pharmacy & Compounding, 78 FR 

57656, 57659 (2013) (citing 

Meetinghouse Community Pharmacy, 

Inc., 74 FR 10073, 10074 n.5 (2009); RX 

Direct Pharmacy, Inc., 72 FR 54070, 

54072 n.4 (2007)). Registrant had the 

right to challenge the Immediate 

Suspension Order before the Agency but 

chose not to. And had Registrant not 

allowed its registration to expire, I 

would have revoked it. 

Accordingly, I will order that the 

controlled substances seized pursuant to 

the Immediate Suspension Order be 

forfeited to the United States. 21 U.S.C. 

824(f). I will also declare that ‘‘[a]ll, 

right, title, and interest in’’ the 

controlled substances that were seized 

pursuant to the Suspension Order have 

vested in the United States. Id. 

Order 

Pursuant to the authority vested in me 

by 21 U.S.C. 824(a) and (d), as well as 

28 CFR 0.100(b), I order that the Order 

of Immediate Suspension issued to Chip 

RX d/b/a City Center Pharmacy be, and 

it hereby is, affirmed. Pursuant to the 

authority vested in me by 21 U.S.C. 

824(f), I order that all controlled 

substances seized pursuant to the Order 

of Immediate Suspension be, and they 

hereby are, forfeited to the United 

States. Pursuant to the authority vested 

in me by 21 U.S.C. 824(f), I also declare 

that all right, title, and interest in all 

controlled substances seized pursuant to 

the Order of Immediate Suspension be, 

and they hereby are, vested in the 

United States. This Order is applicable 

December 6, 2017. 

Dated: October 31, 2017. 

Robert W. Patterson, 

Acting Administrator. 

[FR Doc. 2017–24093 Filed 11–3–17; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Bulk Manufacturer of Controlled 

Substances Application: Cerilliant 

Corporation 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before January 5, 2018. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.33(a), this is notice that on May 23, 

2017, Cerilliant Corporation, 811 

Paloma Drive, Suite A, Round Rock, 

Texas 78665–2402 applied to be 

registered as a bulk manufacturer of the 

following basic classes of controlled 

substances: 

Controlled substance Drug code Schedule 

ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-)4-fluorobenzyl)-1-H-indazole-3-carboxamide) ............ 7010 I 

MDMB-FUBINACA (Methyl-2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) ....................... 7020 I 

MAB-CHMINACA (N-(1-amino-3,3dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) ......... 7032 I 


Pmangrum on DSK3GDR082PROD with NOTICES
51440 Federal Register / Vol. 82, No. 213 / Monday, November 6, 2017 / Notices 

Controlled substance Drug code Schedule 

5F-AMB (Methyl 2-(1-(5-fluoropentyl)-1-1H-indazole-3-carboxamido)-3-methylbutanoate) ............................................ 7033 I 

5F-ADB;5F-MDMB-PINACA (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) ......... 7034 I 

MDMB-CHMICA, MMB-CHMINACA (Methyl 2-(1-(cyclohenxylmethyl)-1H-indole-3-carboxamido)-3,3- 

dimethylbutanoate).

7042 I 

5F-APINACA, 5F-AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1-1H-indazole-3-carboxamide) ................................. 7049 I

U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide) ............................................................... 9547 I 

Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) ................................................................................. 9811 I 

4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide) ......................................... 9824 I 

Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide) ............................................................. 9834 I 

The company plans to manufacture 

small quantities of the listed controlled 

substances to make reference standards 

which will be distributed to its 

customers. 

Dated: October 27, 2017. 

Demetra Ashley, 

Acting Assistant Administrator. 

[FR Doc. 2017–24090 Filed 11–3–17; 8:45 am] 

BILLING CODE 4410–09–P 

NATIONAL AERONAUTICS AND 

SPACE ADMINISTRATION 

[Notice: (16–083)] 

Centennial Challenges: 3D-Printed 

Habitat Challenge 

AGENCY: National Aeronautics and 

Space Administration (NASA). 

ACTION: Notice of Centennial Challenges 

3D-Printed Habitat Challenge Phase 3: 

On-Site Habitat Competition. 

SUMMARY: The 3D-Printed Habitat 

(3DPH) Challenge Phase 3 On-Site 

Habitat Competition is open, and teams 

that wish to compete may now register. 

Centennial Challenges is a program of 

prize competitions to stimulate 

innovation in technologies of interest 

and value to NASA and the nation. The 

3DPH Challenge Phase 3 On-Site Habitat 

Competition is a prize competition with 

a $2,000,000 total prize purse to develop 

and demonstrate capabilities to 

autonomously manufacture through 3Dprinting technologies a habitat on 

another planetary body using mission 

recycled materials and/or local 

indigenous materials. The Phase 3 

competition consists of 5 levels. This 

technology demonstration competition 

has great potential value for terrestrial 

applications. 

DATES: Challenge registration opens 

November 7, 2017, and will remain 

open until February 15, 2018. Early and 

Late registrations are available with 

discount or late fee respectively. 

Competitors will be allowed the option 

to participate in the Virtual 

Construction competitions levels 1 & 4 

only with a reduced registration fee. 

Other important dates: 

May 16, 2018 Level 1: Virtual 

Construction Building Information 

Modeling (BIM)—60% Design Results 

due to Judges 

July 11, 2018 Level 2: Foundation Test 

Results due to Judges 

December 5, 2018 Level 3: Hydrostatic 

Test Results due to Judges 

January 16, 2019 Level 4: Virtual 

Construction BIM—100% Design 

Results due to Judges 

April 29—May 4, 2019 Level 5: Subscale 

Habitat Competition 

ADDRESSES: The Level 5 On-Site 

Subscale Habitat Head-to-Head 

challenge competition will take place at: 

Caterpillar Edwards Demonstration and 

Learning Center, 5801 N. Smith Rd., 

Edwards, IL 61528. 

FOR FURTHER INFORMATION CONTACT: To 

register for or get additional information 

regarding the 3D Printed Habitat 

Challenge, please visit: http://

bradley.edu/challenge For general 

information on the NASA Centennial 

Challenges Program please visit: http:// 

www.nasa.gov/challenges. General 

questions and comments regarding the 

program should be addressed to Monsi 

Roman, Centennial Challenges Program, 

NASA Marshall Space Flight Center 

Huntsville, AL 35812. Email address: 

hq-stmd-centennialchallenges@

mail.nasa.gov. 

SUPPLEMENTARY INFORMATION: 

Summary 

The 3DPH Challenge Phase 3 

Competition (On-Site Habitat) follows 

earlier phases of the Challenge as 

described below. 

• Design Competition (Phase 1)— 

focused on developing innovative 

habitat architectural concepts that take 

advantage of the unique capabilities that 

3D-Printing offers (completed in 2015). 

• Structural Member Competition 

(Phase 2)—focused on the core 3DPrinting fabrication technologies and 

materials properties needed to 

manufacture structural components 

from indigenous materials combined 

with recyclables, or indigenous 

materials alone (completed in 2017). 

The current competition, Phase 3 (OnSite Habitat), will focus on the 

technology for autonomous 3D-printing 

and construction of a complete 1:3 subscale habitat (∼10 m2). This competition 

will involve elements from Phase 1 

design and Phase 2 materials to 

demonstrate the technology for 

autonomous construction needed for 

building a habitat on another planet or 

even on remote locations on Earth. 

A Phase 4 competition (Full-Scale 

Habitat), calling for the development of 

an autonomous 3D-printed construction 

of a full-scale habitat (∼93 m2), is 

planned to be announced at a later date. 

I. Prize Amounts 

The 3D Printed Habitat Challenge 

Phase 3 On-Site Habitat Competition 

purse is $2,000,000 (two million dollars) 

to be disbursed as follows: 

Level 1: Virtual Construction BIM—60% 

Design 

$100,000 total prize money to be 

awarded to top 5 qualifiers based on 

scoring, as articulated in the 

competition rules. 

Level 2: Foundation Test 

$400,000 total prize money to be 

awarded to top 10 qualifiers based on 

scoring, as articulated in the 

competition rules. 

Level 3: Hydrostatic Test 

$600,000 total prize money to be 

awarded to top 8 qualifiers based on 

scoring, as articulated in the 

competition rules. 

Level 4: Virtual Construction BIM— 

100% Design 

$100,000 total prize money to be 

awarded to top 3 qualifiers based on 

scoring, as articulated in the 

competition rules. 

Level 5: Subscale Habitat Competition 

$500,000 to first place 

$200,000 to second place 

$100,000 to third place 

These awards will be made based on 

scoring, as articulated in the 

competition rules. 


Pmangrum on DSK3GDR082PROD with NOTICES